RESEARCH NEWS AND VIEWS FROM ELSEVIER
Patients treated with modern
systemic therapy experienced
excellent outcomes in local
control and overall survival,
regardless of whether they
received radiation therapy.
10
Postmastectomy
radiation
improved local
control but not
overall survival
in women with
breast cancer
Risk of neutropenia-related
hospitalization in patients
who received
colony-stimulating factors
with chemotherapy for breast
cancer
Journal of Clinical Oncology
There was a low to modest
benefit relative to neutropenia-
related hospitalizations associated
with G-CSF prophylaxis in
breast cancer patients being
treated with TC and TCH.
5
Dual block with lapatinib and
trastuzumab vs single-agent
trastuzumab combined with
chemotherapy as neoadjuvant
treatment of HER2-positive
breast cancer: a meta-analysis of
randomized trials
Clinical Cancer Research
Patients with HER2-positive breast
cancer benefit from the neoadjuvant
combination of lapatinib and
trastuzumab, while hormone receptor-
negative patients demonstrate the best
results with taxane monotherapy.
5
Daratumumab, bortezomib,
and dexamethasone
for multiple myeloma
The New England Journal of Medicine
Daratumumab with
bortezomib and dexamethasone
led to significantly increased
progression-free survival,
but also resulted in more
frequent adverse events
compared with bortezomib/
dexamethasone alone.
13
Extramedullary disease in adult
acute myeloid leukemia is common
but lacks independent significance:
analysis of patients in ECOG-ACRIN
Cancer Research Group Trials,
1980–2008
Journal of Clinical Oncology
EMD is relatively common, but not
an independent prognostic factor
in AML. They suggest that AML
treatment decisions should be based
on the presence of recognized AML
prognostic factors, and not on the
presence of EMD.
14
Readers Poll
What’s the ONE
medical app you
can’t live without?
Scan this code or go to
goo.gl/68Uaucto have
your say in this issue’s
PracticeUpdate
Haematology
& Oncology
Readers Poll.
PROSTATE
Special roundup of the 17th
APCC in Melbourne
4
CONFERENCE
ASTRO 2016
A radiation boost is
recommended in patients
with DCIS and ≥10 years
life expectancy following
breast-conserving surgery
and whole breast
radiotherapy
8
Reduced radiation boost
volume is recommended
but craniospinal axis dose
remains unchanged in
average-risk paediatric
medulloblastoma
9
After 10 years,
postmastectomy radiation
is shown to improve local
control but not overall
survival in women with breast
cancer and one to three
positive nodes
10
FEATURE ARTICLE
MicroRNAs in
brain cancer treatment
15
OPINION
If I had to placemy
chip 50 years down
the future onwhat
wewould know, I’d
say it’s probably
going to turn out
to be viruses that
we’re exposed too.
They often end
up integrating
into our genome,
unbeknownst to us.
Dr Steven Toms
15
FORMERLY HAEMATOLOGY & ONCOLOGY NEWS
VOL. 1 • No. 4 • 2016